Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
517
-
Total 13F shares, excl. options
-
120M
-
Shares change
-
+7.51M
-
Total reported value, excl. options
-
$29.2B
-
Value change
-
+$1.98B
-
Put/Call ratio
-
0.92
-
Number of buys
-
266
-
Number of sells
-
-213
-
Price
-
$243.00
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2024
642 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2024.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 517 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 120M shares
of 132M outstanding shares and own 91.2% of the company stock.
Largest 10 shareholders include Capital World Investors (15M shares), VANGUARD GROUP INC (12.5M shares), FMR LLC (12.2M shares), BlackRock Inc. (9.55M shares), WELLINGTON MANAGEMENT GROUP LLP (6.21M shares), BAILLIE GIFFORD & CO (6.03M shares), Capital International Investors (3.89M shares), Dodge & Cox (3.78M shares), STATE STREET CORP (3.53M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (3.49M shares).
This table shows the top 517 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.